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Conclusions:
We demonstrate that chemokine (C-C motif) ligand (CCL) 14, sVEGFR2, and plateletderived growth factor BB are elevated in obesity, and CXCL12, CCL11, and CCL27 are lower in obesity. We found clinically concordant directionality between lean and patients with obesity and before vs after surgery for six cytokines, suggesting that bariatric surgery shifted the cytokine profiles of patients with obesity toward that of lean controls. (J Clin Endocrinol Metab 104: [947] [948] [949] [950] [951] [952] [953] [954] [955] [956] 2019) O besity affects an estimated one-third of adults in the United States, representing a major public health problem (1) . People with obesity are at greater risk of metabolic syndrome, type 2 diabetes, hyperlipidemia, heart disease, and cancer (2, 3) . Obesity is associated with a state of chronic low-grade inflammation, also called "inflammome," characterized by increased circulating cytokine production (4) and immune cell infiltration into adipose tissues (5) (6) (7) . Although many previous studies have investigated one or more independent adipokines and cytokines in obesity, we aim here to concurrently assess a much larger set and conduct a more comprehensive profiling of cytokines, chemokines, and secreted cytokine receptors in people who are lean and people who are obese and in patients with obesity undergoing bariatric surgery.
Previous research has shown that inflammatory cytokines and adipokines are altered in obesity. Members of the interleukin family are involved in the inflammatory process, including IL-1b, IL-1Ra, IL-6, IL-8, and IL-10, and are increased in obesity (8) (9) (10) (11) (12) . Several cytokines, including TNF-a, soluble TNF receptor (sTNFR) 2, plasminogen activator inhibitor 1, and IL-6, have also been shown to contribute to the insulin resistance that develops with obesity (4, (13) (14) (15) (16) (17) . Leptin is an adipocytokine secreted by white adipose tissue that is elevated in obesity and has been correlated with increasing insulin resistance, whereas adiponectin is decreased in obese adipose tissue and circulation (18) (19) (20) .
Bariatric surgery is considered the most effective and sustained long-term treatment of severe obesity and has become an option for treatment of type 2 diabetes in adults (21, 22) . Bariatric surgery leads to significant weight loss in addition to reducing inflammation, insulin resistance, cardiovascular disease, and associated mortality from obesity-associated comorbidities (23) . Studies have demonstrated that C-reactive protein, IL-6, TNF-a, and other proinflammatory cytokines in circulation are reduced by 6 months after bariatric surgery (24) (25) (26) . We have also shown that adipokines change in response to bariatric surgery and the subsequent weight loss, with increases in adiponectin and decreases in leptin (18, 25, 27) .
In this study, we used a bead-based multiplex profiling method to comprehensively investigate a large set of cytokines with inflammatory, immune, and metabolic functions in a cohort of patients who are lean and patients who are obese matched by age, sex, and race. We also studied changes in a subset of these biomarkers in patients with obesity undergoing bariatric surgery. The purpose of this study was to elucidate the extent to which cytokines are altered in obesity and contribute to systemic inflammation. Furthermore, we aimed to investigate how bariatric surgery may alter the cytokine milieu and affect the inflammome. ) with no history of diabetes or cardiovascular disease were recruited from the Johns Hopkins Hospital. Thirty-seven age-, sex-, and ethnicitymatched pairs were included in this cross-sectional analysis. All patients undergoing bariatric surgery were invited to participate in a prospective cohort study. Of these, 25 patients completed both 3-and 6-month follow-up visits. Patients completing the 6-month follow-up were comparable to those who did not.
Research Design and Methods

Study design and participants
Participants were verbally briefed about the study and signed written informed consent forms. All human studies were approved by the Johns Hopkins University School of Medicine Institutional Review Board.
Clinical and laboratory measurements
BMI was calculated as weight (in kilograms) divided by height (in square meters). All blood samples were obtained in the morning after an overnight fast. Blood samples were centrifuged at 3200g for 7 minutes, and serum was aliquoted and stored at 280°C for subsequent assays. Fasting glucose, aspartate aminotransferase (AST), alanine aminotransferase (ALT), cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and hemoglobin A1c (HbA1c) were performed by the Johns Hopkins Pathology Core Laboratory. Serum insulin levels were measured by ELISA (Millipore Human Insulin, Billerica, MA). Insulin resistance was calculated with the homeostasis model assessment of insulin resistance (HOMA-IR) (28) . Human adiponectin levels were measured by ELISA (AdipoGen, Incheon, Korea). Leptin was measured by quantikine ELISA (R&D Systems, Minneapolis, MN).
Intra-assay coefficients of variation were 3.1 6 0.1 (leptin) and 3.4 6 0.4 (adiponectin). Interassay coefficients of variation were 4.3 6 0.9 (leptin) and 4.3 6 1.2 (adiponectin).
Serum cytokine profiling
Serum samples were analyzed with a Luminex instrument (Luminex, Austin, TX) and XPonent 3.1 software (Millipore, Billerica, MA). Assays for 89 human cytokines (covering the majority of the known cytokines) were performed with a Luminex bead-based multiplex system according to manufacturer's protocol (EMD Millipore, Billerica, MA). All available cytokine assays provided by Millipore were included (HSCRMAG-32K, HCYP2MAG-62K, HCYP3MAG-63K, and HCYTOMAG-60K). Some of the cytokines' receptors are synthesized in membranebound form, and proteolytic cleavage generates a soluble version that circulates in plasma. Thus, soluble CD30, soluble interleukin receptors sIL-1RI, sIL-1RII, sIL-2Ra, sIL-4R, and sIL-6R, sTNFR1, sTNFR2, soluble vascular endothelial growth factor receptor (sVEGFR) 1, sVEGFR2, sVEGFR3, soluble glycoprotein 130, soluble epidermal growth factor receptor, and soluble receptor for advanced glycation end-products (sRAGE) were also measured as part of the 89 cytokines profiled. Standards were provided for each human cytokine, from which standard curves were generated. Concentrations were determined for each of the 89 human cytokines relative to an appropriate six-point regression standard curve in which the mean fluorescence for each cytokine standard was transformed into known concentrations (in picograms or nanograms per milliliter). Analyte concentrations, detection limits, and intraassay coefficients of variation were calculated by Millipore Analyst software. Some of the cytokines (21 in total) were below detection of the standard curve; thus, to increase the sensitivity and detection limit of the assay, we also performed the same measurements with an ultrasensitive Luminex assay for 21 of the cytokines (HSTCMAG-28SK). Thirteen markers were still below the limit of detection of the assay and were excluded from the analysis, resulting in 76 evaluable cytokines.
Cytokines were compared in patients with obesity before and after bariatric surgery. The same four Milliplex kits that were used in the first study were again used but only for measuring the analytes (17) found to be significantly different (P , 0.05) between patients who are lean and patients who are obese in the first part of the study.
Statistical analysis
Continuous variables were normally distributed and are presented as mean 6 SEM, with ranges. Categorical variables are expressed as proportions (percentages). Cytokine values were normalized via a logarithmic transformation. Student t test was used to compare demographic and biochemical variables between the obese and lean groups. These analyses were performed with Stata statistical software 11.0 (StataCorp LP, College Station, TX). A P ,0.05 was considered significant.
Obese vs lean analyses
We modeled the effects of obesity (comparing subjects with obesity and lean subjects) via linear regression analysis on natural log-transformed cytokine values. We adjusted for testing multiple cytokines by using the Bonferroni correction, which controls for the familywise error rate. We also performed hierarchical clusterings on the Euclidean distances of both cytokines across subjects (to compare how similar different cytokines were) and subjects across cytokines (to compare how similar different subjects were across cytokines).
Presurgery vs postsurgery analyses
We modeled the effects of surgery (comparing baseline and then 3-and 6-month follow-up) via linear mixed effects modeling, with the individual as a random intercept. We natural-log transformed the cytokine values to better fulfill the assumptions of linear modeling. These analyses were performed in the R statistical software package, version 3.2.
Results
Patient demographics and baseline clinical characteristics
Our cross-sectional cohort included 74 patients (12 men and 62 women) with a mean age of 41.4 6 1.3 years (range 23 to 66 years). BMI of the lean group (n = 37) was 22.1 6 0.3 kg/m 2 (range 17.6 to 26) and the obese group (n = 37) was 46.2 6 1.2 kg/m 2 (range 35.6 to 68.6). The obese and lean groups were matched by age, sex, and ethnicity. Both groups included 32 (86%) white and 5 (14%) black subjects. Baseline metabolic parameters were within the normal range for all laboratory testing in the lean group. The baseline characteristics of all study subjects are summarized in Table 1 . The obese group showed a significantly higher mean BMI, fasting glucose, HbA1c, insulin, HOMA, ALT, triglyceride, and leptin levels when compared with the lean control group. HDL cholesterol and adiponectin were significantly lower in the obese group compared with the lean group. None of the patients in the lean group were on diabetes, hypertension, or hyperlipidemia medications. In the obese group, 12 had a diagnosis of type 2 diabetes (11 of 12 were on diabetes medications), 24 had hypertension (22 of 24 were on antihypertensive medications), and 6 had hypercholesterolemia (6 of 6 were on lipid-lowering medication).
Cytokine profiling in patients who are lean and patients who are obese Of the 76 inflammatory markers we examined, 17 were significantly associated with obesity, 12 of which had a P , 0.01, as shown in Fig. 1 . Thirteen of these markers were significantly higher in obesity, including sTNFR2, sTNFR1, hemofiltrate CC chemokine (HCC) 1/chemokine (C-C motif) ligand (CCL) 14, growth-related oncogene (GRO)/ chemokine (C-X-C motif) ligand (CXCL) 1, macrophage inflammatory protein (MIP) 3b/CCL19, sVEGFR2, plateletderived growth factor (PDGF) BB, IL-1RA, IL-6, sIL-6R, IL-16, epithelial cell-derived neutrophil-activating peptide (ENA) 78/CXCL5, and thrombopoietin (TPO). In contrast, stromal cell-derived factor (SDF) 1/CXCL12, eotaxin/ cutaneous T-cell-attracting chemokine (CCL11), sRAGE, and CTACK/CCL27 were all significantly lower in obesity compared with lean controls (29) . We performed correlation analyses of all the cytokines with clinical variables demonstrated here in a correlation heatmap (Fig. 2) . Three of the cytokines (sVEGFR2, sTNFR1, and sTNFR2) were positively correlated with weight and BMI, whereas sRAGE was inversely correlated with weight and BMI. sTNFR2 was positively correlated with fasting glucose, HOMA-IR, and HbA1c. We also analyzed the relationship of the cytokines across all patients, both lean and with obesity, in a dendrogram to demonstrate similarities between different cytokines and similarities between different subjects across cytokines (29) . Cytokines that appear closer together in the dendrogram have levels that are more closely correlated across subjects.
Some of the patients with obesity were on medications for diabetes, hypertension, or hyperlipidemia, so we adjusted for each of these medication categories. Of the 17 significant cytokines listed above, only IL-16 and ENA78/CXCL15 lost significance when we controlled for diabetes medications (P = 0.08 and P = 0.2, respectively). When we adjusted for antihypertensive medications, sVEGFR2 lost significance but was directionally consistent (P = 0.06, logFC 0.16), in addition to sRAGE, IL-16, ENA78/CXCL15, and TPO. Finally, when we adjusted for statins, all cytokines retained significance except ENA78/CXCL15 (P = 0.05) and TPO (P = 0.08).
Cytokines predictive of weight loss after bariatric surgery
We analyzed the association of inflammatory cytokines with weight loss after bariatric surgery. Fourteen (37%) of the patients underwent RYGB, compared with 23 (63%) who underwent VSG. Of the 37 patients with obesity enrolled at the time of bariatric surgery, 32 had follow-up data at 3 months, and 26 had follow-up data at 6 months. Mean BMI before surgery was 46.2 kg/m 2 , 38.9 kg/m 2 at 3 months, and 35.6 kg/m 2 at 6 months after surgery (P , 0.001). Higher baseline levels of sIL-1R2 and sIL-6R were predictive of weight loss at 3 and 6 months. Of all the cytokines, baseline levels of eight cytokines were predictive of weight loss at 3 months, whereas five were predictive of weight loss at 6 months ( Table 2) .
Decreased levels of sVEGFR2 and increased levels of SDF1 after bariatric surgery
We investigated these 17 cytokines in a cohort of 25 patients who completed follow-up at 3 and 6 months after bariatric surgery (Table 3) . Most (17 of 25) of these patients were the same as in the first cohort and had similar baseline characteristics, but all 25 patients completed follow-up at 3 months and 6 months. Both weight (P , 0.01) and BMI (P , 0.01) decreased after surgery. Other clinical changes included increased HDL cholesterol (P , 0.01) and decreased triglycerides (P = 0.01), decreased ALT (P , 0.01) with no change in AST (P = 0.8), and a significant decline in HbA1c (P , 0.01) (29) . Before surgery, nine patients had a diagnosis of diabetes (eight of nine on diabetes medications), and by 6 months, only five had diabetes necessitating treatment. Before surgery, 16 had hypertension (14 of 16 on antihypertensive medications), and at 6 months, 11 had hypertension (eight on medications). Before surgery, six patients had hyperlipidemia (six of six on statins) and at 6 months, five had hyperlipidemia (four on medication). We controlled for these medications in our analysis with no change in results. Adiponectin increased (P , 0.01), and leptin decreased (P , 0.01) after surgery. sVEGFR2 is elevated in obesity (P , 0.01), with a significant decrease 6 months after bariatric surgery (P = 0.01), as shown in Fig. 3 . SDF1 is low in obesity (P , 0.01), and significantly increases 3 months after bariatric surgery (P = 0.03). Interestingly, MIP-3b showed an initial increase after bariatric surgery, followed by a decrease that was close to significant (P = 0.06). We found clinically concordant directionality between the lean and obesity analyses and the pre-and post-bariatric surgery analyses for six cytokines, two of which were significant (sVEGFR2 and SDF1), suggesting that bariatric surgery shifted the cytokine profiles of patients with obesity toward that of lean controls (Fig. 4) .
Discussion
The association between obesity and systemic inflammation has been well established. Many previous studies have investigated one or a few inflammatory markers, adipokines, or cytokines in the setting of obesity. To our knowledge, our current study profiled the largest set of cytokines, chemokines, and secreted cytokine receptors in patients with and without obesity and in patients with obesity undergoing bariatric surgery. Using a bead-based multiplex method, we simultaneously quantified the circulating levels of 76 cytokines by using only a small volume of blood. Based on our results from this crosssectional study, we also investigated 17 cytokines in patients with morbid obesity undergoing bariatric surgery. Although some of our findings support previous literature, we have demonstrated that HCC-1/CCL14, sVEGFR2, and PDGF-BB are significantly elevated in obesity and that SDF1/CXCL12, eotaxin/CCL11, and CTACK/CCL27 are lower in obesity. Our findings of sVEGFR2 and SDF1 were also confirmed by our longitudinal cohort study, where levels after bariatric Figure 1 . Cytokine levels differentially expressed between patients with and without obesity (at P ,0.01). P values calculated by two-tailed t test.
doi: 10.1210/jc.2018-02245 https://academic.oup.com/jcemsurgery were comparable to those of nonobese controls, demonstrating significant improvements in inflammation after weight loss surgery. These results also support the concept that the inflammome of obesity is characterized by the presence of proinflammatory cytokines and chemokines, with improvements after weight loss surgery.
As in previous studies, we found the proinflammatory cytokines of IL-1Ra, IL-6, and sIL-6R to be elevated in obesity. Meier et al. (9) also showed that IL-1Ra decreased after gastric bypass surgery in a cohort of 15 patients with morbid obesity, but we did not see a significant change in IL-1Ra at 3 or 6 months after surgery. Several authors have also shown IL-6 to be positively correlated with BMI, with increased levels in patients with obesity and in those with impaired glucose tolerance and type 2 diabetes (10, 30, 31) . Similar to our findings in obesity, sIL-6R is elevated in adults with metabolic syndrome (32) but is lower in children and adolescents with obesity (33) . A previous study by Kitahara et al. (34) used similar methods to examine large numbers of cytokines in patients who participated in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. They similarly found that MIP-3b/CCL19, ENA78, and sTNFR2 were significantly associated with BMI. Other investigators have demonstrated that subjects with obesity have higher sTNFR1, sTNFR2, IL-16, and TPO (35) (36) (37) . GROa (GRO1/CXCL1) has been shown to be higher in women with obesity compared with lean controls, positively correlated with glycemia, and inversely correlated with insulin sensitivity (37) . We similarly saw an increase in GRO in obesity. Our study also confirms previous findings that sRAGE is decreased in obesity (38) .
In our cross-sectional study, we demonstrated several cytokine changes. HCC-1/CCL14a is a hemofiltrate chemokine that functions as a chemoattractant for different types of leukocytes and circulates in high concentrations in human plasma (39) . HCC-1/CCL14 has not been studied in human obesity, and we demonstrated that HCC-1 is elevated in obesity. PDGF-BB is a cytokine that mediates profibrotic activity in the liver and other tissues. This isoform is produced by activated macrophages associated with adipose tissue inflammation (40) . In a study of patients with metabolic syndrome, they were found to have lower levels of PDGF-BB as compared with overweight controls. This finding was in contrast to an earlier study by Pang et al. (41) , who reported an increase of PDGF serum levels in leptin-deficient obese (ob/ob) mice relative to wild type littermate controls. Our results are consistent with this early study in mice, with patients with obesity showing higher levels of PDGF-BB compared with lean controls. Furthermore, we found eotaxin/CCL11 and CTACK/CCL27 to be lower in patients with obesity. Eotaxin/CCL11 is an eosinophilspecific chemokine thought to be involved in eosinophilic inflammatory diseases (42) , and here we found that eotaxin levels were lower in obesity. CTACK/CCL27 is a cytokine that may play a role in homing lymphocytes to cutaneous sites (43, 44) , but its relationship to human obesity has not been established until now. We found that CTACK levels were lower in obesity compared with lean controls. Consistent with previous studies, we also demonstrated that obesity is associated with systemic inflammation and improves with bariatric surgery (45) (46) (47) . Bariatric surgery is an effective treatment of morbid obesity, and its effects on reducing overall systemic inflammation may be related to less overall adipose tissue and reduced macrophage infiltration of adipose tissue. The obesity-associated inflammatory state appears to improve by 1 to 3 months after bariatric surgery, with some authors suggesting that surgery may exacerbate the inflammatory state in the early postoperative period (46, 47) . In our study, we showed that sVEGFR2 is higher in obesity and significantly decreased 6 months after bariatric surgery. When we examined changes in this secreted cytokine by type of surgery, there was a significant decline in sVEGFR2 after RYGB but not after VSG (P = 0.02 vs 0.24). Vascular endothelial growth factors (VEGFs), including VEGF-A and VEGF-B, play a role in regulating both physiologic and pathologic angiogenesis. As one of the most highly vascularized tissues in the body, adipose tissue maintains a close relationship with the vasculature. Angiogenesis and adipogenesis are directly linked, because developing adipose tissue requires blood vessels, and the VEGF family plays a major role in this crosstalk (48, 49) . VEGF-A expression increases during adipocyte differentiation and has been shown to increase in obesity and decrease after bariatric surgery (50) (51) (52) . In mouse studies using VEGFR2 blockers to inhibit angiogenesis in diet-induced obese mice, treated mice had significantly lower body weights than control animals, suggesting that antiangiogenic treatment by VEGFR2 blockade may limit adipose tissue expansion (53) . These results suggest that sVEGFR2 plays a major role in the inflammome, and with its close link to angiogenesis, it should be a focus of future investigation in targets for treatment of obesity.
SDF1/CXCL12 was initially identified as a chemokine in bone marrow-derived stromal cells, until Kim et al. (54) showed increased expression of SDF1 in the adipose tissue of diet-induced obese mice. They suggested that in adipocytes, SDF1 induces monocyte migration via its receptor chemokine CXCR4, thereby leading to macrophage recruitment and infiltration of the adipose tissue, contributing to inflammation and insulin resistance (54) . Additional in vitro and in vivo studies by Shin et al. (55) showed that SDF1 is overexpressed in obese adipose tissues. Addition of SDF1 induced signaling that led to reduced insulin-mediated signaling and glucose uptake, suggesting insulin desensitization in the obese state. When they ablated SDF1 in adipocytes they found increased insulin sensitivity in adipose tissues and the whole body (55) . In contrast to these studies, we found SDF1 levels to be lower in obesity, with a significant increase in circulating levels in patients who underwent bariatric surgery (P , 0.01). It is possible that mouse and human expressions of this chemokine are different. Furthermore, our longitudinal study of patients before and after bariatric surgery includes multiple time points where SDF1 increases, validating these results. We also analyzed whether medication use affected cytokine levels, and SDF1 retained its significance even after we controlled for medications used for diabetes, hypertension, and hyperlipidemia. Interestingly, when we analyzed changes in this cytokine by type of surgery, there was a significant increase in SDF1 after VSG but not after RYGB (P = 0.02 vs 0.57).
The inflammatory milieu changes significantly in the setting of severe obesity and, with weight loss from bariatric surgery, shifts toward that of subjects without obesity. In the most comprehensive analysis performed in the setting of obesity and bariatric surgery, we have identified several proinflammatory cytokines, chemokines, and adipokines that contribute to the inflammome of obesity. By further investigating and focusing on the mechanisms of these inflammatory markers, we may be able to improve prevention and treatments for obesity and identify those who will respond best to bariatric surgery. For example, patients in our cohort with higher sIL-1R2 and sIL-6R levels before surgery had greater weight loss at both 3 and 6 months after surgery.
Among the strengths of this study are the large number of cytokines studied and the participants in the cohort study serving as their own controls, thereby allowing us to determine the relative metabolic improvements and changes in adipokines after bariatric surgery. Because the patients were followed at two time points after surgery, we confirmed that the observed changes in cytokine levels persist over time. However, there are also limitations, including the small sample size. Furthermore, we relied on BMI to measure adiposity, which does not distinguish between lean and fat mass. Although we know that surgery itself can affect cytokine levels in the postoperative period, it is also possible that recent infection could affect cytokine levels. We did not exclude patients who had recent infections or measure C-reactive protein in this cohort, and this is a limitation of the data.
Conclusions
In the obesity-associated inflammome, we identified several inflammatory and cytokine changes including higher HCC-1/CCL14, sVEGFR2, and PDGF-BB, and lower SDF1/CXCL12, eotaxin/CCL11, and CTACK/ CCL27. Although the inflammatory state slowly improves after weight loss surgery, sVEGFR2 shows a significant decline by 6 months, and SDF1 increases significantly 3 months after bariatric surgery. Additional investigation of these markers and their mechanistic changes in obesity and after weight loss surgery will elucidate their potential as treatment targets or predictors of outcomes.
